Clinical Trial Update: To Compare Treatment With Doxorubicin or Capecitabine for Metastatic Breast Cancer in Women 60 Years and Older [Phase 3]

View source ↗

Summary

Phase 3 trial comparing doxorubicin versus capecitabine for metastatic breast cancer in women 60 years and older has been terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• Capecitabine (capecitabine)
• Doxorubicin (doxorubicin)

Snippet

Sponsor: Johnson & Johnson Pharmaceutical Research & Development, L.L.C. | Conditions: Metastatic Breast Cancer | Phase 3 | Status: TERMINATED